IBIO: iBio Inc Price to Sales
iBio, Inc. utilizes AI to develop antibodies, fully outsourcing production and testing to third-party contractors. The historical P/S trend visualizes market expectations, where 45.10 indicates the value of this parameter. Currently, iBio, Inc. has no recurring revenue, relying instead on the success of its developments. Meanwhile, deep integration with global partners optimizes research costs and minimizes operational risks.
Metric breakdowns and analytics for iBio Corp (IBIO)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
IBIO - Net Profit|Future Profit iBio, Inc.|IBIO - Price to Earnings Ratio|Market Cap to Projected Earnings iBio Inc|IBIO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio iBio Corp|IBIO - Operating profit EBITDA|Earnings per share for the last twelve months iBio|IBIO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ibioinc.com|IBIO - Earnings per share growth in current year|Expected net earnings per share growth next year iBio, Inc.
- issuer revenue and sales details:
Summary company analytics:ibioinc.com, IBIO
The P/S ratio compares the market capitalization of iBio, Inc. (IBIO) to its generated revenue, determining the cost of each dollar of sales. For a biotech firm facing liquidity shortages and costly AI development, this metric reflects the extent to which investor expectations are inflated relative to actual cash flows. By analyzing the historical P/S values of iBio, Inc. (IBIO), one can identify points of extreme overvaluation or undervaluation of the asset. Long-term consensus requires benchmarking this metric against the rate of capital dilution.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|IMVT: P/S Multiple|KNSA (kiniksa.com) - Price-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Adaptive Biotech (ADPT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Celldex (CLDX)|AUPH - Price to Sales|BioCryst - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VERA|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TRML|PGEN (Precigen, Inc.) - P/S Multiple|Market Cap to Revenue pharming.com (PHAR)|Market Cap to Revenue NKTR (Nektar Therapeutics Inc.)|Price-to-Revenue Coefficient Upstream Bio, Inc.|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Price-to-Revenue Coefficient Immunome Bio (IMNM)|Gossamer Bio, Inc. - P/S Multiple|KALV: Price-to-Revenue Ratio|SEPN: P/S Multiple|PVLA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Savara Corp|Price to Sales Rigel Corp RIGL|Price-to-Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Price-to-Sales Ratio|P/S Multiple ENGN (enGene)|Market Capitalization-to-Revenue Ratio RAPT|Aerovate - P/S Multiple|ACRS - P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|tizianalifesciences.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cabaletta Bio|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|P/S Multiple THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Eledon Pharmaceuticals - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AGEN|Climb Bio - P/S Multiple|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|aTyr (ATYR) - Price-to-Revenue Ratio|Market Cap to Revenue Adagene Inc.|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Shattuck Therapeutics (STTK)|Market Cap to Revenue EQ (Equillium, Inc.)|P/S Multiple connectbiopharm.com (CNTB)|Price-to-Revenue Ratio Immunic IMUX|ATRA: Market Cap to Revenue Ratio|InflaRx GmbH - P/S Multiple|Price to Sales x4pharma.com|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|INMB (INmune Bio Corp) - P/S Multiple|Price-to-Revenue Ratio BRNS|P/S Multiple KZR|Price-to-Revenue Coefficient sabbiotherapeutics.com|Price-to-Revenue Ratio Akari Therapeutics Plc AKTX|Enlivex Therapeutics Ltd (ENLV) - Price to Sales|QTTB: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOVX (GeoVax Corp)|EDSA: P/S Multiple|CARM - Price-to-Revenue Coefficient|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Ratio BOLT (Bolt Bio)|P/S Multiple HCWB|Market Cap to Revenue aptevotherapeutics.com APVO|AIM ImmunoTech Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient Aditxt Inc. (ADTX)|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|HIND: P/S Multiple|REVB (Revelation Biosciences Corp) - Price-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|scinai.com (SCNI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Price-to-Sales Ratio|IGM Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
